Prelude Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $539K | Buy |
+31,139
| New | +$539K | 0.05% | 416 |
|
|
2025
Q1 | – | Sell |
-31,255
| Closed | -$997K | – | 1080 |
|
|
2024
Q4 | $997K | Buy |
31,255
+2,300
| +8% | +$73.4K | 0.06% | 311 |
|
|
2024
Q3 | $835K | Buy |
28,955
+16,021
| +124% | +$462K | 0.05% | 383 |
|
|
2024
Q2 | $496K | Buy |
+12,934
| New | +$496K | 0.03% | 484 |
|
|
2024
Q1 | – | Sell |
-8,240
| Closed | -$493K | – | 1186 |
|
|
2023
Q4 | $493K | Buy |
+8,240
| New | +$493K | 0.03% | 445 |
|
|
2023
Q3 | – | Sell |
-2,861
| Closed | -$261K | – | 982 |
|
|
2023
Q2 | $261K | Buy |
+2,861
| New | +$261K | 0.02% | 614 |
|
|
2022
Q4 | – | Sell |
-11,293
| Closed | -$771K | – | 1167 |
|
|
2022
Q3 | $771K | Buy |
+11,293
| New | +$771K | 0.03% | 490 |
|
|
2021
Q3 | – | Sell |
-4,434
| Closed | -$280K | – | 1357 |
|
|
2021
Q2 | $280K | Sell |
4,434
-10,957
| -71% | -$692K | 0.01% | 985 |
|
|
2021
Q1 | $660K | Buy |
+15,391
| New | +$660K | 0.02% | 490 |
|
|
2020
Q3 | – | Sell |
-3,956
| Closed | -$129K | – | 1354 |
|
|
2020
Q2 | $129K | Buy |
3,956
+448
| +13% | +$14.6K | 0.01% | 596 |
|
|
2020
Q1 | $94K | Buy |
+3,508
| New | +$94K | 0.01% | 368 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 1397 |
|
|
2019
Q1 | – | Sell |
-11,790
| Closed | -$156K | – | 1339 |
|
|
2018
Q4 | $156K | Buy |
+11,790
| New | +$156K | 0.01% | 571 |
|